<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400179</url>
  </required_header>
  <id_info>
    <org_study_id>TPU S-1301</org_study_id>
    <nct_id>NCT00400179</nct_id>
    <nct_alias>NCT00128609</nct_alias>
  </id_info>
  <brief_title>A Safety and Efficacy Study in Patients With Gastric Cancer</brief_title>
  <official_title>An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating
      the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced
      gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be
      randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm).
      Patients will be stratified by number of metastatic sites (one vs. more than one), locally
      advanced or metastatic disease, prior adjuvant therapy (yes or no), measurable or
      non-measurable disease, and center.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Survival</measure>
    <time_frame>The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).</time_frame>
    <description>Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Data cutoff was 07 March 2008 (12 months after last patient randomized).</time_frame>
    <description>The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Data cutoff was 07 March 2008 (12 months after last patient was randomized).</time_frame>
    <description>Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.</time_frame>
    <description>The time from randomization to date of first documented PD or date of death, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.</time_frame>
    <description>The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1053</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Arm A, S-1 25 mg/mÂ² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1/Cisplatin</intervention_name>
    <description>In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/cisplatin</intervention_name>
    <description>In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient must meet all of the following inclusion criteria to be eligible for enrollment
        in this study:

          -  Has given written informed consent

          -  Has histologically confirmed, unresectable, locally advanced (Stage IV) or metastatic
             gastric cancer, including adenocarcinoma of the gastro-esophageal junction

          -  Has measurable or evaluable but non-measurable disease, defined as follows:

               -  Measurable Disease - Patients with measurable disease as defined by RECIST
                  criteria, i.e., the presence of at least one measurable lesion. A measurable
                  lesion is one that can be accurately measured in at least one dimension with the
                  longest diameter &gt;_ 20 mm using conventional techniques or &gt;_ 10 mm using spiral
                  Computed Tomography (CT)scan. Locally recurrent disease (other than primary) is
                  accepted if there is at least one measurable lesion (i.e. peritoneal mass, lymph
                  node, etc.)

               -  Evaluable but Non-measurable Disease - Patients with all lesions below the limits
                  defined above for measureable disease (i.e., longest diameter &lt; 20 mm with
                  conventional techniques or &lt; 10 mm with spiral CT) excluding those patients with
                  only a primary lesion and/or with only non-evaluable cancer such as bone
                  metastases, ascites, pleural or pericardia effusions, lymphangitic carcinomatosis
                  of the skin or lung, previously irradiated lesions not in progression, or
                  peritoneal carcinomatosis &lt; 10 mm in diameter with conventional imaging
                  techniques.

          -  No prior palliative chemotherapy is permitted. Adjuvant and /or neo-adjuvant
             chemotherapy is permitted if more than 12 months have elapsed between the end of
             adjuvant or neo-adjuvant therapy and first recurrence. This does not qualify as 1st
             line therapy.

          -  Is able to take medications orally

          -  Is &gt;_ 18 years of age

          -  Is at least 3 weeks from prior major surgery

          -  Is at least 4 weeks from prior radiotherapy

          -  Has a ECOG performance status 0 to 1

          -  Has adequate organ function as defined by the following criteria:

               -  AST (SGOT) and ALT (SGPT) &lt;_ 2.5 x ULN; if liver function abnormalities are due
                  to underlying liver metastasis, AST (SGOT) and ALT (SGPT) &lt;_ 5 x ULN

               -  Total serum bilirubin of &lt;_ 1.5 x ULN

               -  Absolute granulocyte count of &gt;_ 1,500/mm (i.e. &gt;_ 1.5 x 10/L by International
                  Units (IU)

               -  Platelet count &gt;_ 100,000/mm (IU: &gt;_ 100 x 10/L

               -  Hemoglobin value of &gt;_ 9.0 g/dL

               -  Calculated creatinine clearance &gt;_ 60 mL/min (Cockcroft-Gault formula)

          -  Is willing and able to comply with scheduled visits, treatment plans, laboratory tests
             and other study procedures

        Exclusion Criteria:

        Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if
        any of the following conditions are observed:

          -  Has had a treatment with any of the following within the specified timeframe prior to
             study drug administration:

               -  Any prior palliative chemotherapy or any previous therapy for malignancy,
                  including any chemotherapy, immunotherapy, biologic or hormonal therapy, within
                  the past 5 years.

               -  Adjuvant or neo-adjuvant therapy within the past 12 months

               -  Concurrent treatment with any investigational anti-cancer agent

               -  Prior cisplatin as neo-adjuvant and /or adjuvant chemotherapy with cumulative
                  dose &gt; 300 mg/m

               -  &gt; 25% of marrow-bearing bone radiated

               -  Concurrent treatment with an investigational agent or within 30 days from
                  randomization

               -  Concurrent enrollment in another clinical study

          -  Has a serious illness or medical condition(s) including, but not limited to the
             following:

               -  Known brain or leptomeningeal metastases

               -  Uncontrolled ascites requiring drainage at least twice a week

               -  Other malignancies within the past 5 years, except adequately treated
                  carcinoma-in-situ of the cervix or non-melanoma skin cancer

               -  Myocardial infarction within the last 6 months, severe/unstable angina,
                  congestive heart failure New York Heart Association (NYHA) class III or IV

               -  Chronic nausea, vomiting or diarrhea

               -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
                  (AIDS-related illness

               -  Psychiatric disorder that may interfere with consent and/or protocol compliance

               -  Known neuropathy, Grade 2 or higher

               -  Other severe acute or chronic medical or psychiatric condition or laboratory
                  abnormality that may increase the risk associated with study participation or
                  study drug administration, or may interfere with the interpretation of study
                  results, and in the judgement of the Investigator would make the patient
                  inappropriate for entry into this study

          -  Is receiving concomitant treatment with drugs interacting with S-1. The following
             drugs are prohibited because there may be an interaction with S-1:

               -  Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole (may enhance S-1
                  activity)

               -  Allopurinol (may diminish S-1 activity

               -  Phenytoin (S-1 may enhance phenytoin activity)

               -  Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 activity)

          -  Is receiving concomitant treatment with drugs interacting with 5-FU:

               -  Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole(may enhance 5-FU
                  activity)

               -  Allopurinol (may diminish 5-FU activity)

               -  Phenytoin (5-FU may enhance phenytoin activity)

          -  Is receiving concomitant treatment with drugs interacting with cisplatin:

               -  Phenytoin (cisplatin may diminish phenytoin activity)

               -  Aminoglycosides (should be avoided within 8 days after cisplatin administration)

               -  Ethyol (may diminish cisplatin activity

          -  Is a pregnant or lactating female

          -  Has known hypersensitivity to 5-FU or cisplatin

          -  Patients with reproductive potential who refuse to use an adequate means of
             contraception (including male patients)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Benedetti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Oncology, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clearview Cancer Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ronald Yanagihara</name>
      <address>
        <city>Gilroy</city>
        <state>California</state>
        <zip>95020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Memorial Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hematology/Oncology</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Oncology Associates</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandar Rosemurgy</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Straub Clinic and Hospital</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Cancer Care Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHS Lovelace Medical Group,LLC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Center Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoo Chun, MD</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Associates of Rockland</name>
      <address>
        <city>New City</city>
        <state>New York</state>
        <zip>10956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Bern Cancer Care</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology and Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexington Oncology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hopital Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <results_first_submitted>January 6, 2012</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2012</results_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multicenter study was conducted between May 18, 2005 and March 7, 2008 in 24 countries including the United States. Study centers were also located in Canada, Eastern and Western Europe, South America, Australia, and ex-Soviet Union block of nations.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>S-1/Cisplatin</title>
          <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
        </group>
        <group group_id="P2">
          <title>5-FU/Cisplatin</title>
          <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="527">Signed informed consent form and randomized</participants>
                <participants group_id="P2" count="526"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="521">Received Treatment</participants>
                <participants group_id="P2" count="508"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator judgment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization error/patient ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>S-1/Cisplatin</title>
          <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
        </group>
        <group group_id="B2">
          <title>5-FU/Cisplatin</title>
          <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="521"/>
            <count group_id="B2" value="508"/>
            <count group_id="B3" value="1029"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Baseline Measure Data (descriptive stats, median)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" lower_limit="18" upper_limit="83"/>
                    <measurement group_id="B2" value="59.0" lower_limit="18" upper_limit="85"/>
                    <measurement group_id="B3" value="59.0" lower_limit="18" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="382"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                    <measurement group_id="B2" value="438"/>
                    <measurement group_id="B3" value="885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body surface area (BSA) Categories</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;/=1.29 m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.30-1.49 m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.50-1.69 m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.70-1.89 m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.90-2.09 m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.10-2.29 m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/=2.30 m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>0=Fully active, able to carry on all pre-disease performance without restriction
1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="308"/>
                    <measurement group_id="B3" value="603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tissue Type</title>
          <description>Patients can have more than one tissue type and are included under each type.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Papillary adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tubular adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Well-differentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately-differentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poorly differentiated adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Signet-ring cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucinous adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenocarcinoma NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poorly differentiated cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anatomical Location of Primary Lesion</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stomach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="438"/>
                    <measurement group_id="B2" value="417"/>
                    <measurement group_id="B3" value="855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastroesophageal junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach and gastroesophageal junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of Disease</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 metastatic site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/=2 metastatic sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Measurability</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Measureable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="499"/>
                    <measurement group_id="B2" value="485"/>
                    <measurement group_id="B3" value="984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-measurable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonevaluable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No disease present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions.</description>
        <time_frame>Data cutoff was 07 March 2008 (12 months after last patient randomized).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-1/Cisplatin</title>
            <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
          </group>
          <group group_id="O2">
            <title>5-FU/Cisplatin</title>
            <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions.</description>
          <units>Percentage of patients in each group</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" lower_limit="24.7" upper_limit="33.8"/>
                    <measurement group_id="O2" value="31.9" lower_limit="27.3" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3952</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR)</title>
        <description>Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions.</description>
        <time_frame>Data cutoff was 07 March 2008 (12 months after last patient was randomized).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-1/Cisplatin</title>
            <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
          </group>
          <group group_id="O2">
            <title>5-FU/Cisplatin</title>
            <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR)</title>
          <description>Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.8" upper_limit="7.4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0808</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>The time from randomization to date of first documented PD or date of death, whichever occurred first.</description>
        <time_frame>From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-1/Cisplatin</title>
            <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
          </group>
          <group group_id="O2">
            <title>5-FU/Cisplatin</title>
            <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>The time from randomization to date of first documented PD or date of death, whichever occurred first.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.0" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.4" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9158</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF)</title>
        <description>The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first.</description>
        <time_frame>From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-1/Cisplatin</title>
            <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
          </group>
          <group group_id="O2">
            <title>5-FU/Cisplatin</title>
            <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF)</title>
          <description>The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.7" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.7" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0320</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Survival</title>
        <description>Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.</description>
        <time_frame>The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>S-1/Cisplatin</title>
            <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
          </group>
          <group group_id="O2">
            <title>5-FU/Cisplatin</title>
            <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Survival</title>
          <description>Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="521"/>
                <count group_id="O2" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="7.9" upper_limit="9.5"/>
                    <measurement group_id="O2" value="7.9" lower_limit="7.2" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1983</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>S-1/Cisplatin</title>
          <description>In the S-1/cisplatin arm, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with a glass of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour intravenous (IV) infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment.</description>
        </group>
        <group group_id="E2">
          <title>5-FU/Cisplatin</title>
          <description>In the 5-FU/cisplatin arm, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="521"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="521"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="521"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="521"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="521"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Vitreious floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="521"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="521"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="521"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="521"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Prepyloric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Retroperitoneal fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="521"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Catheter thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="521"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="521"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Broncopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="521"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Device migration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Stent occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Urine electrolytes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkalosis hypochloraemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="521"/>
                <counts group_id="E2" events="41" subjects_affected="32" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Metastases to ovary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Tumour perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="521"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Iliac artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pelvis venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="521"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="521"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="514" subjects_at_risk="521"/>
                <counts group_id="E2" subjects_affected="504" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="404" subjects_affected="229" subjects_at_risk="521"/>
                <counts group_id="E2" events="380" subjects_affected="234" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="383" subjects_affected="149" subjects_at_risk="521"/>
                <counts group_id="E2" events="588" subjects_affected="240" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="174" subjects_affected="92" subjects_at_risk="521"/>
                <counts group_id="E2" events="190" subjects_affected="116" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="224" subjects_affected="91" subjects_at_risk="521"/>
                <counts group_id="E2" events="254" subjects_affected="117" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="54" subjects_affected="26" subjects_at_risk="521"/>
                <counts group_id="E2" events="126" subjects_affected="34" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="18" subjects_at_risk="521"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="521"/>
                <counts group_id="E2" events="38" subjects_affected="35" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="521"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="76" subjects_affected="29" subjects_at_risk="521"/>
                <counts group_id="E2" events="75" subjects_affected="44" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="521"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="62" subjects_affected="32" subjects_at_risk="521"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="81" subjects_affected="18" subjects_at_risk="521"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="778" subjects_affected="321" subjects_at_risk="521"/>
                <counts group_id="E2" events="913" subjects_affected="342" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="616" subjects_affected="260" subjects_at_risk="521"/>
                <counts group_id="E2" events="693" subjects_affected="281" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="329" subjects_affected="152" subjects_at_risk="521"/>
                <counts group_id="E2" events="331" subjects_affected="195" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="219" subjects_affected="131" subjects_at_risk="521"/>
                <counts group_id="E2" events="205" subjects_affected="114" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="296" subjects_affected="120" subjects_at_risk="521"/>
                <counts group_id="E2" events="219" subjects_affected="133" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="125" subjects_affected="66" subjects_at_risk="521"/>
                <counts group_id="E2" events="85" subjects_affected="67" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="86" subjects_affected="46" subjects_at_risk="521"/>
                <counts group_id="E2" events="41" subjects_affected="30" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="74" subjects_affected="33" subjects_at_risk="521"/>
                <counts group_id="E2" events="321" subjects_affected="153" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="49" subjects_affected="31" subjects_at_risk="521"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="521"/>
                <counts group_id="E2" events="54" subjects_affected="42" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="521"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="521"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="16" subjects_at_risk="521"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="521"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="505" subjects_affected="205" subjects_at_risk="521"/>
                <counts group_id="E2" events="329" subjects_affected="200" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="124" subjects_affected="88" subjects_at_risk="521"/>
                <counts group_id="E2" events="152" subjects_affected="96" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="112" subjects_affected="72" subjects_at_risk="521"/>
                <counts group_id="E2" events="80" subjects_affected="61" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="55" subjects_affected="55" subjects_at_risk="521"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="81" subjects_affected="53" subjects_at_risk="521"/>
                <counts group_id="E2" events="56" subjects_affected="46" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" events="36" subjects_affected="35" subjects_at_risk="521"/>
                <counts group_id="E2" events="49" subjects_affected="42" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="27" subjects_at_risk="521"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="521"/>
                <counts group_id="E2" events="330" subjects_affected="152" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="521"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="521"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="32" subjects_at_risk="521"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="521"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="521"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="157" subjects_affected="148" subjects_at_risk="521"/>
                <counts group_id="E2" events="173" subjects_affected="164" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="43" subjects_affected="37" subjects_at_risk="521"/>
                <counts group_id="E2" events="72" subjects_affected="61" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="521"/>
                <counts group_id="E2" events="78" subjects_affected="62" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="521"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="521"/>
                <counts group_id="E2" events="25" subjects_affected="18" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="521"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="22" subjects_at_risk="521"/>
                <counts group_id="E2" events="61" subjects_affected="29" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="521"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood LDH increased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="521"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="521"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="521"/>
                <counts group_id="E2" events="46" subjects_affected="27" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="521"/>
                <counts group_id="E2" events="44" subjects_affected="24" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="521"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="306" subjects_affected="164" subjects_at_risk="521"/>
                <counts group_id="E2" events="310" subjects_affected="177" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="81" subjects_affected="63" subjects_at_risk="521"/>
                <counts group_id="E2" events="114" subjects_affected="79" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="91" subjects_affected="52" subjects_at_risk="521"/>
                <counts group_id="E2" events="74" subjects_affected="52" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="38" subjects_at_risk="521"/>
                <counts group_id="E2" events="51" subjects_affected="41" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="36" subjects_at_risk="521"/>
                <counts group_id="E2" events="133" subjects_affected="85" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="521"/>
                <counts group_id="E2" events="62" subjects_affected="30" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="521"/>
                <counts group_id="E2" events="63" subjects_affected="46" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="521"/>
                <counts group_id="E2" events="45" subjects_affected="36" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="521"/>
                <counts group_id="E2" events="32" subjects_affected="21" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="521"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="521"/>
                <counts group_id="E2" events="43" subjects_affected="30" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="58" subjects_affected="45" subjects_at_risk="521"/>
                <counts group_id="E2" events="57" subjects_affected="44" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="521"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="16" subjects_at_risk="521"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="128" subjects_affected="53" subjects_at_risk="521"/>
                <counts group_id="E2" events="72" subjects_affected="36" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="127" subjects_affected="50" subjects_at_risk="521"/>
                <counts group_id="E2" events="72" subjects_affected="51" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="128" subjects_affected="48" subjects_at_risk="521"/>
                <counts group_id="E2" events="79" subjects_affected="50" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="80" subjects_affected="42" subjects_at_risk="521"/>
                <counts group_id="E2" events="59" subjects_affected="44" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="521"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="521"/>
                <counts group_id="E2" events="35" subjects_affected="33" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="173" subjects_affected="40" subjects_at_risk="521"/>
                <counts group_id="E2" events="129" subjects_affected="67" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="521"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="521"/>
                <counts group_id="E2" events="39" subjects_affected="31" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="98" subjects_affected="37" subjects_at_risk="521"/>
                <counts group_id="E2" events="99" subjects_affected="45" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="37" subjects_affected="30" subjects_at_risk="521"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="89" subjects_affected="29" subjects_at_risk="521"/>
                <counts group_id="E2" events="46" subjects_affected="33" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="521"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="521"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="31" subjects_at_risk="521"/>
                <counts group_id="E2" events="111" subjects_affected="104" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="28" subjects_at_risk="521"/>
                <counts group_id="E2" events="27" subjects_affected="13" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="521"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="53" subjects_affected="27" subjects_at_risk="521"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="62" subjects_affected="20" subjects_at_risk="521"/>
                <counts group_id="E2" events="22" subjects_affected="13" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="521"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="521"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="521"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="521"/>
                <counts group_id="E2" events="35" subjects_affected="23" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Taiho agreements vary with individual investigators, but do not prohibit any from publishing. Taiho is provided time to review material discussing trial results (generally 30 to 120 days with possible extension), and can remove undisclosed confidential, proprietary and intellectual property rights-related information. Authors have final control and approval of publication content of final study results. The investigator agrees not to publish any results before the first multicenter publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fabio Benedetti, MD, Chief Medical Officer</name_or_title>
      <organization>Taiho Pharma USA, Inc.</organization>
      <phone>609-750-5300</phone>
      <email>benedetti@taihopui.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

